Typical GI Side Effects with Tigecycline
Tigecycline, a glycylcycline antibiotic used for complicated infections, commonly causes gastrointestinal (GI) issues, primarily nausea and vomiting. In clinical trials, nausea occurred in 26% of patients, vomiting in 18%, and diarrhea in 12%.[1][2] These rates are higher than with comparators like levofloxacin (nausea 8%, vomiting 4%).[1]
How Common Are They Across Studies?
Pooled data from Phase 3 trials (over 1,700 patients) show:
- Nausea: 25.5% (severe in 3.9%)
- Vomiting: 17.7% (severe in 3.0%)
- Diarrhea: 12.5%
Most events are mild to moderate, starting early in treatment and resolving without stopping therapy. Discontinuation due to GI effects happens in about 4% of cases.[1][3]
Why Are GI Effects So Frequent?
Tigecycline disrupts gut flora and has a broad-spectrum action, irritating the GI tract. Twice-daily IV dosing (first dose 100 mg, then 50 mg) contributes, unlike less frequent regimens. Food doesn't mitigate this, as it's IV-only.[2][4]
What Do Patients Experience in Practice?
Real-world reports align with trials: nausea affects 20-30% in hospital settings, often dose-dependent. Elderly patients or those with abdominal infections see slightly higher rates (up to 35% nausea).[3][5] Symptoms peak in the first 48 hours.
How Does Tigecycline Compare to Other Antibiotics?
| Antibiotic | Nausea % | Vomiting % | Diarrhea % |
|------------|----------|------------|------------|
| Tigecycline | 26 | 18 | 12 |
| Levofloxacin | 8 | 4 | 5 |
| Vancomycin | 7 | 6 | 10 |
| Linezolid | 4 | 2 | 8 |[1][2]
Tigecycline has the highest GI burden among similar agents, leading some guidelines to reserve it for multidrug-resistant cases.
Management and When to Worry
Premedicate with antiemetics (e.g., ondansetron) to cut nausea by half. Slow infusion over 60 minutes helps. Serious risks like C. difficile diarrhea are rare (<2%), but monitor for dehydration.[4][5] FDA label notes GI effects as most common reason for discontinuation.
Sources
[1]: Tigecycline Prescribing Information (Pfizer)
[2]: FDA Approval Summary
[3]: ClinicalTrials.gov Pooled Analysis (NCT00079547 et al.)
[4]: IDSA Guidelines on Tigecycline Use
[5]: Post-Marketing Surveillance Data (DrugPatentWatch.com)